FRONTAGE HOLDINGS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 HKD | -1.54% |
|
-2.29% | -44.83% |
| 04-01 | Frontage Holdings' Net Profit Plunges 59% in 2023 | MT |
| 03-28 | Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 298M 2.34B 408M | Sales 2025 * | 346M 2.71B 473M | Capitalization | 331M 2.59B 452M |
|---|---|---|---|---|---|
| Net income 2024 * | 17M 133M 23.24M | Net income 2025 * | 25M 196M 34.17M | EV / Sales 2024 * | 1.42 x |
| Net Debt 2024 * | 92.86M 727M 127M | Net Debt 2025 * | 86.09M 674M 118M | EV / Sales 2025 * | 1.21 x |
| P/E ratio 2024 * |
19.6
x | P/E ratio 2025 * |
12.9
x | Employees | 1,759 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 28.55% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.54% | ||
| 1 week | -2.29% | ||
| Current month | -11.11% | ||
| 1 month | -12.93% | ||
| 3 months | -20.00% | ||
| 6 months | -32.28% | ||
| Current year | -44.83% |
1 week
1.21
1.32
1 month
1.211.47
Current year
1.212.27
1 year
1.212.58
3 years
1.219.18
5 years
1.219.18
10 years
1.219.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 17-05-31 | |
Song Li
FOU | Founder | 66 | 00-12-31 |
Jun Gao
DFI | Director of Finance/CFO | 48 | 01-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Fan Li
BRD | Director/Board Member | 55 | 18-03-31 |
Erh Fei Liu
BRD | Director/Board Member | 65 | 18-03-31 |
Song Li
FOU | Founder | 66 | 00-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.28 | -1.54% | 1,558,000 |
| 24-04-25 | 1.3 | +4.00% | 5,300,000 |
| 24-04-24 | 1.25 | -3.85% | 2,324,468 |
| 24-04-23 | 1.3 | 0.00% | 2,236,000 |
| 24-04-22 | 1.3 | -0.76% | 632,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Frontage Holdings Corporation is a holding company. The principal activities of the Company and its subsidiaries are to provide laboratory and related services to pharmaceutical and agrochemical companies. The Company is a contract research organization (CRO) providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals. Its segments include North America and the Peopleâs Republic of China (PRC). The North America segment includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research, early stage clinical/bioequivalence and chemistry services in the USA and Canada. PRC segments include laboratory testing, CMC, preclinical research, early stage clinical/ bioequivalence and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) and safety and toxicology.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.1635
USD
Average target price
0.2178
USD
Spread / Average Target
+33.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.83% | 331M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 1521 Stock
